Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats.
Structural disruption of gut microbiota contributes to the development of non-alcoholic fatty liver disease (NAFLD) and modulating the gut microbiota represents a novel strategy for NAFLD prevention. Although previous studies have demonstrated that curcumin alleviates hepatic steatosis, its effect on the gut microbiota modulation has not been investigated.



Next generation sequencing and multivariate analysis were utilized to evaluate the structural changes of gut microbiota in a NAFLD rat model induced by high fat-diet (HFD) feeding.



We found that curcumin attenuated hepatic ectopic fat deposition, improved intestinal barrier integrity, and alleviated metabolic endotoxemia in HFD-fed rats. More importantly, curcumin dramatically shifted the overall structure of the HFD-disrupted gut microbiota toward that of lean rats fed a normal diet and altered the gut microbial composition. The abundances of 110 operational taxonomic units (OTUs) were altered by curcumin. Seventy-six altered OTUs were significantly correlated with one or more hepatic steatosis associated parameters and designated 'functionally relevant phylotypes'. Thirty-six of the 47 functionally relevant OTUs that were positively correlated with hepatic steatosis associated parameters were reduced by curcumin.



These results indicate that curcumin alleviates hepatic steatosis in part through stain-specific impacts on hepatic steatosis associated phylotypes of gut microbiota in rats.



Compounds with antimicrobial activities should be further investigated as novel adjunctive therapies for NAFLD.
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Wenhuan
W
Feng
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Hongdong
H
Wang
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Pengzi
P
Zhang
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Caixia
C
Gao
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Junxian
J
Tao
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Zhijuan
Z
Ge
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China. Electronic address: zhudalong@nju.edu.cn.
Dalong
D
Zhu
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China. Electronic address: biyan@nju.edu.cn.
Yan
Y
Bi
D000818:Animals; D003474:Curcumin / Q000494:pharmacology*; D059305:Diet, High-Fat; D000069196:Gastrointestinal Microbiome / Q000187:drug effects* / Q000502:physiology; D059014:High-Throughput Nucleotide Sequencing; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000382:microbiology; D051381:Rats; D017207:Rats, Sprague-Dawley
D003474:Curcumin
Curcumin; Gut microbiota; Hepatic steatosis